Corbus Pharmaceuticals Advances Oncology and Obesity Pipeline with Key FDA Alignment and Upcoming Data Readouts
Event summary
- Corbus reached broad FDA alignment on the registration path for CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancer.
- Completed enrollment in the 16-week CANYON-1 study (n=240) for CRB-913 in obesity, with topline data expected this summer.
- Reported a net loss of $23.0 million for Q1 2026, up from $17.0 million in Q1 2025, due to increased clinical development expenses.
- CRB-701 and CRB-913 are on track for registrational studies and data presentations at ASCO 2026.
The big picture
Corbus Pharmaceuticals is positioning itself at the intersection of oncology and obesity treatment, two high-growth areas in biopharmaceuticals. The company's strategic focus on CRB-701 and CRB-913 aligns with the increasing demand for targeted therapies in cancer and innovative solutions for obesity management. The upcoming data readouts and regulatory milestones will be critical in determining the company's trajectory in these competitive markets.
What we're watching
- Regulatory Pathway
- Whether the FDA alignment will expedite the registrational study for CRB-701 and reduce regulatory hurdles.
- Clinical Data
- The impact of the upcoming ASCO 2026 data presentations on CRB-701's differentiated profile in HNSCC and cervical cancer.
- Market Potential
- The pace at which CRB-913 can establish itself as a unique oral obesity drug with a non-GLP-1 and non-incretin mechanism of action.
Related topics